Older Age and Vaccination Protect Against Transaminase Elevation in Pediatric SARS-CoV2

Antonia Fernandez Ovale MD^a, Cassandra Charles BA^b, Janet Rosenbaum PhD^c, Priscila Villalba-Davila MD^a, Mauricio Mora MD^d, Shagun Sharma MBBS^e, Vivian Vega Lemus MD^e, Saema Khandakar MD^f, Thomas Wallach MD^e

Affiliations: ^a SUNY Downstate Health Sciences University, Department of Pediatrics; ^b SUNY Downstate Health Sciences University Research Foundation; ^c SUNY Downstate Health Sciences University, School of Public Health, Department of Biostatistics and Epidemiology; ^d Woodhull Hospital, Department of Pediatrics, ^e SUNY Downstate health Sciences University, Department of Pediatrics Division of Pediatric Gastroenterology; ^f Kings County Medical Center, Department of Pediatrics

Address correspondence to: Dr. Thomas Wallach, MD. 450 Clarkson Avenue Brooklyn, NY 11203 Ph: (718) 270-4714, Fax: (718) 270-8223, email: <u>Thomas.wallach@downstate.edu</u>

Short title: Age/Vaccination Decrease Pediatric SARS-CoV2 Hepatitis

Conflict of Interest Disclosures (includes financial disclosures): No conflicts of interest to disclose

Funding/Support: No funding was secured for this study.

Role of Funder/Sponsor (if any): No Funder/Sponsor.

Clinical Trial Registration (if any): N/A

Word Count: 2464

Figures and Tables: 4

Abbreviations: Aspartate Aminotransferase (AST), Alanine Aminotransferase (AST), Socioeconomic Status (SES),

Article Summary

Cross sectional study of an urban pediatric population demonstrates SARS-CoV2 transaminase elevation linked with younger age, unvaccinated status, and higher level of care.

1 Abstract:

- 2 <u>Objectives</u>: SARS-CoV2 infection is reported to induce transaminase elevations. There are case
- 3 reports of severe liver injury in adult SARS-CoV2 patients and some have theorized that acute
- 4 SARS-CoV2 infection may be a driver of severe liver injury in children. While pediatric hepatic
- 5 injury has previously been described, clear shifts in immunogenic response secondary to prior
- 6 immune exposure and vaccination since initial reports from 2020 warrant further evaluation. We
- 7 sought to identify the impact of variant shifts and vaccination on this phenomenon in children.
- 8 <u>Methods</u>: A retrospective, cross-sectional study of pediatric SARS-CoV2 patients seen at two
- 9 hospital facilities in an urban neighborhood in New York City between March 2020 and March
- 10 2022 was conducted via chart review. Data was extracted relating to patient's demographics, 11 clinical presentation, including the level of care and the laboratory results of comprehensive
- 12 metabolic panels (CMP).
- 13 <u>Results</u>: 133 pediatric cases were identified as having positive SARS-CoV2 and CMP obtained in
- 14 the same visit. Patients were predominantly Black (79.2%) and non-Hispanic (87%) with a mean
- 15 age of 9.2 years. Risk of transaminase elevation was increased in younger patients and patients
- 16 with higher level of care. BMI was not a risk factor noted for transaminase elevation. Vaccination
- 17 decreased degree, not incidence, of transaminase elevation but given low rates of vaccination
- 18 unable to determine significance of protective efficacy.
- 19 Conclusions: Our study has identified a profound increased risk of transaminase elevation in
- 20 younger patients, the absence of BMI as a correlating factor in our primarily Black patient
- population, a shift towards non-specific AST elevation with variant windows and a strong signal
 of vaccine protection.
- 23

25

26

27

28

30

31

32

33

34

24 What is Known:

- SARS-CoV2 can cause Transaminemia, and in rare cases, possible fulminant hepatic injury
- Pediatric SARS-CoV2 infections are statistically milder than adult.
- SARS-Cov2 case severity and complications like multisystem inflammatory syndrome in children have declined over time

29 What is New:

- With population immunity and variant shifts transaminase elevations increasingly may not be of hepatic origin
- Risk of transaminase elevation is substantially higher in younger patients, and decreases with age
- Vaccines are protective against degree of transaminase elevation, and likely against incidence of transaminase elevation, although further study is needed.
- 35 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

47

48 <u>Introduction</u>

49

50 It has been well-documented since the onset of the pandemic that SARS-CoV2 infections can 51 trigger elevations to serum transaminases, thus raising concerns for direct liver injury¹. While 52 direct liver failure as a result of SARS-CoV2 appears to be rare and often perceived to be secondary to multi-organ injury in severely ill patients², it is not fully elucidated how acute viral 53 54 infection impacts the pediatric liver nor how this picture has changed over time with evolved variants and acquired population immunity³. In 2021, a perceived cluster of pediatric fulminant 55 56 liver failure led to rampant speculation that SARS-CoV2 was driving incidence, and raising 57 concern for further increase. Further investigation led to foundational work demonstrating the role 58 of adeno-associated virus but no evidence of SARS-CoV2 involvement was determined besides 59 seroprevalence, which at that time was known to be wide^{4, 5}.

60

61 In the adult population, it has been reported that approximately 20 to 30% of patients who were 62 hospitalized due to SARS-CoV2 acute infection presented with acute liver injury (ALI), characteristically presenting with mild cholestasis and elevation of transaminases². While this rate 63 64 may vary with disease severity and history of pre-existing conditions, it suggests that for adult patient's liver involvement may be predictive of more severe disease⁶, although it is unclear 65 whether the impact on the liver was due to either severe illness or viral infection directly. 66 67 Mechanistic work has suggested that direct viral injury to the liver is plausible⁷. Pediatric case series studies have suggested the viruses have the potential to drive liver failure⁸ vet further 68 69 understanding of the natural history of this disease in pediatrics is needed, especially as meaningful 70 interventions such as vaccination have been deployed.

72 As rates of fulminant liver injury have remained essentially unchanged over time, it is unlikely 73 that acute SARS-CoV2 infections have led to an increased need for liver transplantation or 74 frequently driven direct morbidity and mortality from hepatic injury. However, it remains a serious 75 possibility that SARS-CoV2 may present an ongoing risk for severe liver injury, especially given evidence of increased capacity to drive autoimmunity, including liver specific disease⁹⁻¹¹. There is 76 77 an absence of confirmed findings for relatively rare events such as pediatric liver failure that is not 78 exculpatory of possible linkage. It is also likely that the pathology has shifted over time from when previous studies of viral interaction with the pediatric liver^{12, 13} were reported which is 79 80 evidenced by overall decreasing clinical acuity and a rapid decline in Multisystem Inflammatory Syndrome in Children (MIS-C) with different waves of variant infection¹⁴. 81

82

In this study, we sought to retrospectively assess the natural history, population immunity and 83 84 associated risks of acute lab-confirmed SARS-CoV2 infection on liver function at neighboring 85 hospital facilities in an urban neighborhood in Brooklyn, NY between March 2020 and March 86 2022. As SARS-CoV2 vaccination rates remain low in children, our work is particularly relevant in understanding the value of vaccination in children which remains contentious and highly 87 important¹⁵. We hypothesized that transaminase elevations would be associated with increased 88 89 body mass index (BMI), a higher level of treatment care and more prevalent in the early phases of 90 the epidemic. We anticipated milder symptomology and lower rates of transaminase elevation in 91 those children improvement from prior immune exposure via infection or vaccination.

92

93

94

95 <u>Methods</u>

96 SUNY Downstate IRB and the Kings County STAR Committee approved the retrospective review 97 of the electronic medical records of pediatric patients evaluated for SARS-CoV2 at two 98 neighboring New York City institutions between March 2020 and March 2022. Our review 99 included all patients up to and including 18 years of age with confirmed SARS- CoV2 infection 100 via nasal swab- derived real- time reverse polymerase chain reaction, as well as a comprehensive 101 metabolic panel performed at the same visit. We reviewed over 3452 cases and identified 133 102 which met our criteria.

103

104 Clinical, demographic, laboratory and anthropometric data were collected. Patients were evaluated 105 at the emergency department prior to being admitted to the pediatrics floor or pediatric intensive 106 care unit. No patients were repeated. The following demographic covariates were extracted from 107 the patient chart: age in months, male versus female sex assigned at birth, Black vs non-Black race, 108 and Hispanic versus non-Hispanic ethnicity. We had the following health status measures: BMI, 109 preexisting conditions, and asthma status.

110

Patients that were diagnosed with MIS-C during the hospitalization were excluded. Patients with sickle cell disease were also excluded from our analysis due to the possible increase of transaminases due underlaying hemolysis. All the patients included in our study that had a prior value of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) available in electronic medical record, had normal values for transaminases prior to the acute infection by SARS-CoV-2. Patients with prior elevation of liver enzymes were excluded. AST and ALT elevation were assigned using cutoffs from Bussler et al (AST >46, ALT >20)¹⁶. Transaminemia trends were only followed up until discharge from the hospital. No follow up results were includedonce patients were discharged from the unit.

120

Patients were categorized into two groups, one with elevated transaminases at initial encounter or during hospitalization and another group that presented with normal transaminases at initial encounter and during the hospital course, if admitted.

124

Gastrointestinal symptoms were considered positive if the patient presented with at least one of the following: nausea, vomiting, diarrhea, abdominal pain and decrease oral intake. Obesity was defined as body mass index (BMI) above 95th percentile and/or BMI \geq 30 kg/m² as applicable. Level of care was determined depending on the admission location or discharged from the emergency department after initial encounter with no follow up.

130

SARS-CoV-2 variants were estimated variant type based on population sequencing data from New York State. This was estimated by grouping patients on timelines according to the first time each of the main variants was detected in New York until the time a subsequent variant was detected. Vaccination status of each patient was reviewed as per city wide immunization records of New York and the presence of SARS-CoV-2 antibody was accounted only when performed during the acute SARS-CoV-2 infection hospitalization.

137

138

139

140

141 Analysis

We evaluated the association between elevated transaminases and continuous variables (age in months, AST/ALT ratio, BMI z-score) using Kolgomorov-Smirnov to evaluate the difference between the areas between the curves and the non-parametric Wilcoxon test. We used ggplot2 to produce plots, <u>https://ggplot2.tidyverse.org</u>) in R 4.3.1¹⁷. Elevated transaminases were present in 53/133 patients. Multivariate Poisson regression was used to assess the outcome of elevated transaminases in these patients.

148

149 Vaccination status is highly endogenous to age and date of presentation because the FDA issued 150 emergency use authorization for the vaccine approvals by age groups, and the vaccine was first 151 authorized for ages 12 and older on May 10, 2021 and for ages 5-11 on October 29, 2021, and the 152 vaccine was not available for under 5 until June 2022. In our sample, only 3 patients ages 5-11 153 were vaccinated. We cannot distinguish between the effects of older age and vaccination status. 154 SARS-CoV-2 antibody status was coded as true for children who tested positive on the antibody 155 test and coded negative for children who either were not administered an antibody test or who 156 tested negative on the antibody test: the test may have been differentially administered to children 157 who had elevated transaminases.

158

We used causal mediation analysis to evaluate how much of the association between vaccination
and elevated transaminases is mediated by age, using the mediation package¹⁸.

161

162

163

164 <u>Results</u>

165 133 patients meeting our criteria were included. Patients age was from 0 to 18 years old at the time 166 of encounter with a mean age of 9.2 years old. 52.9% of the patients were male and 45.5% of the 167 patients did not have a comorbidity. Most of our study population was black and non-Hispanic 168 with 79.2% and 87% respectively. No patients had progressive liver injury or evidence of liver 169 failure or complications of liver injury.

170

171 56% of patients presented with one or more gastrointestinal symptoms. 47.2% patients with 172 elevated transaminases presented with one or more gastrointestinal symptom at initial encounter. 173 There was no association between the presence of gastrointestinal symptoms and transaminase 174 elevation status (p-value = 0.20). There was also no statistical significance between vaccinated and 175 non-vaccinated patients and the presence of gastrointestinal symptoms at onset (p-value = 0.2). 176 There was no difference in BMI between patients that had elevated transaminases and the patients 177 that did not (p-value = 0.2).

178

Higher level of care was statistically associated with risk of transaminase elevation (p-value <
0.001). Patients with normal AST and ALT values were more likely to be seen in the ED and
subsequently discharged with 61% of the patients versus 32% of the patients that had elevated
transaminases.

183

In this patient population, 39.8% had elevated transaminases and 10.5% were vaccinated against
SARS-CoV2. Vaccinated children had lower AST: median 17.5 interquartile range (14.2, 28) vs
34.0 IQR (23.0, 52) (Figure 1). Among vaccinated children, the prevalence of transaminase

elevation was 21.4% and among unvaccinated children, the prevalence was 42.0%, but this
difference is not statistically significant. However, AST levels in unvaccinated patients were
significantly higher (34.0 vs 17.5, p <0.001). There was no significant difference in mean ALT
level. (Table 1).

191

192 Younger children were more likely to have elevated transaminases p 0.0001. Patients with normal 193 transaminase levels were on average 5 years older and more likely to be 5-11 and 12+ years old. 194 For each year of age, there were 7% fewer cases of transaminase elevation (PR = 0.93, 95% CI (0.89, 0.97)). Patients older than 12 years old had 62% lower risk of elevated transaminases than 195 196 ages 0-11 years old. (Table 2) Rates of elevated transaminases appeared to increase by 197 predominant variant type, with 9/29 (31%) of wild type window patients, 3/10 (30%) of alpha 198 window patients, 9/23 (29.1%) delta window patients, and 32/71 (45.1%) for omicron window 199 patients. AST/ALT ratio increased during the omicron window.

200

Children who were vaccinated presented during the Omicron-prevalent period (since November
202 2021), were more likely to have preexisting conditions (79% vs. 44%) more likely to be 5 years
203 older at median (175 months vs. 102 months), and lower median AST/ALT ratio (1.4 vs. 1.9)
204 (Table 1). Vaccinated children had a higher mean BMI than never-vaccinated children (25.6 vs
205 21.3) (Table 1).

206

In causal mediation analysis, 51% of the effect of the effect of the vaccine on transaminase elevation is mediated by a binary indicator for being age 12 or older, controlling for preexisting condition and presenting during omicron (p=0.04). In a second analysis, 69% of the effect of the

effect of the vaccine on transaminase elevation is mediated by age in months, controlling for preexisting condition and presenting during omicron (p=0.02). However, the percentage of the effect of the effect of the vaccine on transaminase elevation is mediated by age in months controlling for preexisting condition and BMI class is not statistically significant (p=0.08).

214

215 <u>Discussion</u>

While other studies have in part characterized the impact of SARS-CoV2 on the pediatric liver, 216 217 this is the first reported work we are aware of to assess alterations to this behavior over variant 218 windows, the first to assess vaccine protection, and the first to review this in a population of 219 majority african descent and a correspondingly low risk of NAFLD. A focus on a minoritized and 220 low-income population is also highly relevant, as this population remains most at risk of SARS-CoV2 infection¹⁹. We note: a significant age association (higher risk in younger children), a shift 221 222 in characteristic of transaminase elevation over the variant windows, an absence of a BMI 223 association in this primarily Black cohort, and a significant difference in AST elevation and likely 224 difference in overall risk of transaminase elevation in vaccinated patients. Our most significant 225 finding is the likely protective effect of vaccination, although due to the timing of our data and the strong age association of transaminase elevation risk, we were not able to determine significance 226 227 in this study despite a wide practical variation and severity range between vaccinated and 228 unvaccinated patients.

We have noted that pediatric patients with elevated transaminases were more likely to require higher level of care, although in the absence of a prospective study examining serial measurements and outcomes it is not clear if this reflects a risk factor or an outcome of severe illness.

Interestingly, BMI, which has been felt to be a major risk factor both for SARS-CoV2 severity and
transaminase elevation secondary to non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty
liver disease (NAFLD) ^{20, 21}, was not relevant, displaying no increased risk of transaminase
elevation. However, as our hospital center serves a patient population with atypical demographics
(see high percentage of Black race in demographics) this may be an outlier reflecting a specific
resistance to NASH/NAFLD due to polymorphisms such as PNPLA-3 or MBOAT7²².

Interestingly, children that were vaccinated presented with less incidence of elevated 238 239 transaminases than non-vaccinated children (42 versus 21%, p-value 0.2%), although it was not 240 statistically significant due to previously discussed limitation on the age range of vaccinated 241 patients, and the strong correlation of young age and elevated transaminases. Level of 242 transaminase elevation was significantly lower in vaccinated patients (AST 17.5 vs. 34.0, p = 0.002) suggesting a degree of protective impact. This is likely a function of age/limitations on 243 244 when vaccines were available in young children, and it seems highly likely that in a larger study a 245 strong vaccine protection would be noted.

Our study returned other notable findings. First, while we had theorized that GI infection may predispose to transaminase elevation, no connection was noted (Table 2). Second, we observed that with variant progression and population immunity levels there were shifts to the AST/ALT ratio (The DeRitis ratio) The ratio represents the time course and aggressiveness of disease that would be predicted from the relatively short half-life of AST (18 h) compared to ALT (36 h), and can be used to infer origin of transaminase elevation²³. As the AST/ALT ratio increased over the time (Figure 2), it may be that transaminase elevations are increasingly of extra hepatic origin.

Acute illness can also increase AST due to his extra hepatic presence in the muscle, heart andkidney, which aligns with our finding that level of care was linked to transaminase elevation.

In summary, this retrospective cross-sectional study of SARS-CoV2 associated hepatic injury and transaminase elevation has clearly identified major risk factors of young age and disease severity, and highly suggests a strong protective effect from vaccination. It also suggests that increasingly transaminase elevation in this population may not be primarily hepatic, although further study is needed. This study was limited by its retrospective nature, lack of reliably trended results, the bias towards severity inherent in requiring lab work (as frequently mild infections do not result in serum testing), and population size. With that said, several patients had transaminase elevations of significant size, suggesting risk in rare cases for fulminant hepatitis. This work presents a further argument towards the value of pediatric vaccination, although additional larger studies are indicated.

References:

- 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
- 2. Sobotka LA, Esteban J, Volk ML, et al. Acute Liver Injury in Patients Hospitalized with COVID-19. Dig Dis Sci 2022;67:4204-4214.
- 3. Li P, Liu Y, Cheng Z, et al. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management. Biomed Pharmacother 2022;154:113568.
- 4. Jones JM, Manrique IM, Stone MS, et al. Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022. MMWR Morb Mortal Wkly Rep 2023;72:601-605.
- 5. Lewis L, van Wylick C, Mulder DJ. A systematic review of the proposed etiologies of the 2021-2022 outbreaks of pediatric acute hepatitis of unknown etiology. Front Pediatr 2023;11:1285348.
- 6. Wang M, Wu D, Liu CH, et al. Predicting progression to severe COVID-19 using the PAINT score. BMC Infect Dis 2022;22:498.
- 7. Zhao B, Ni C, Gao R, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. Volume 11, 2020:771-775.
- 8. Antala S, Diamond T, Kociolek LK, et al. Severe Hepatitis in Pediatric Coronavirus Disease 2019. J Pediatr Gastroenterol Nutr 2022;74:631-635.
- 9. Rosenbaum J, Ochoa KC, Hasan F, et al. Epidemiologic Assessment of Pediatric Inflammatory Bowel Disease Presentation in NYC During COVID-19. medRxiv 2022:2022.03.23.22272167.
- 10. Saad MA, Alfishawy M, Nassar M, et al. COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases. Curr Rheumatol Rev 2021;17:193-204.
- 11. Terebuh P, Olaker VR, Kendall EK, et al. Liver abnormalities following SARS-CoV-2 infection in children 1 to 10 years of age. Family Medicine and Community Health 2024;12:e002655.
- 12. Sumner MW, Florin TA, Kuppermann N, et al. Liver transaminase concentrations in children with acute SARS-CoV-2 infection. Clinical Biochemistry 2023;118:110588.
- 13. Perez A, Cantor A, Rudolph B, et al. Liver involvement in children with SARS-COV-2 infection: Two distinct clinical phenotypes caused by the same virus. Liver Int 2021;41:2068-2075.
- 14. Eleftheriou I, Maritsi D, Lampidi S, et al. Decreasing Incidence of the Multisystem Inflammatory Syndrome in Children Over 3 Pandemic Waves. Pediatr Infect Dis J 2023;42:122-124.
- 15. Brodin P. Immune responses to SARS-CoV-2 infection and vaccination in children. Semin Immunol 2023;69:101794.
- Bussler S, Vogel M, Pietzner D, et al. New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase): Effects of age, sex, body mass index, and pubertal stage. Hepatology 2018;68:1319-1330.
- 17. Wickham H. ggplot2: Elegant Graphics for Data Analysis (Use R). Springer-Verlag 2016.

- 18. Tingley D, Yamamoto T, Hirose K, et al. mediation: R Package for Causal Mediation Analysis. Journal of Statistical Software 2014;59:1 38.
- 19. Sahli S, Størdal K. Systematic review of socioeconomic factors and COVID-19 in children and adolescents. Acta Paediatr 2024.
- 20. Schwimmer JB, Dunn W, Norman GJ, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010;138:1357-64, 1364.e1-2.
- 21. Ohno M, Dzúrová D. Body Mass Index and Risk for COVID-19-Related Hospitalization in Adults Aged 50 and Older in Europe. Nutrients 2022;14.
- 22. Bonacini M, Kassamali F, Kari S, et al. Racial differences in prevalence and severity of non-alcoholic fatty liver disease. World J Hepatol 2021;13:763-773.
- 23. Botros M, Sikaris KA. The de ritis ratio: the test of time. Clin Biochem Rev 2013;34:117-30.

Table 1: Demographics and Biomarkers at Time of Presentation by Vaccination Status

 Table 2: Demographics and Results by Transaminase Elevation Status

Figure 1: Violin Plot Summary of a) AST and b) ALT elevation by vaccination status.

Figure 2: Change in Transaminase Elevation Behavior by Variant Window. A) AST/ALT ratio by window. B) ALT log scale by window. C) AST log scale by window.





Table 1: Demographics and biomarkers at time of presentation by vaccination status				
TADIE T. DEMOSTADNICS AND DIOMARKERS AT TIME OF DRESENTATION DV VACCINATION STATUS	Table 1. Demographics and	l hiomorkoro ot timo o	f procoptation h	uvaccination status
	Table T: Demographics and	i Diomarkers at time c	n presentation p	

	No vaccine (n=119)	Vaccine (n=14)	P-value
Transaminemia	50 (42.0%)	3 (21.4%)	0.2
AST (highest), median, IQR	34.0 (23.0, 52)	17.5 (14.2, 28)	<0.001
AST elevations			0.2
None [Normal AST ≤ 46]	85 (71.4)	14 (100)	
Mild [Abnormal, less than 2x ULN]	29 (24.4)	0	
Moderate [Between 2-5x ULN]	4 (3.4)	0	
Severe [More than 5x ULN]	1 (0.8)	0	
AST/ALT ratio, median, IQR	1.90 (1.36, 2.54)	1.40 (1.06, 1.85)	0.02
ALT, median, IQR	17.0 (12.0, 22.5)	14.5 (10.8, 18.5)	0.2
Random glucose, median, IQR	97.0 (89.0, 107.0)	96.0 (88.0, 121.5)	0.9
Albumin, median, IQR	4.50 (4.1, 4.8)	4.35 (4.1, 4.8)	0.8
Alkaline phospotase, median, IQR	208 (113, 258)	117.5 (60.8, 220)	0.1
Platelets, median, IQR	267 (207, 368)	298.5 (235.8, 362.3)	0.5
Total bilirubin, median, IQR	0.40 (0.2, 0.6)	0.40 (0.2, 0.6)	0.8
Age (months), median (interquartile range) (range)	108 (26, 180) (Range: 1-216)	186 (156, 204) (Range: 84-223)	0.001
Age group			0.007
0-4 years	34 (28.6%)	0	
5-11 years	40 (33.6%)	3 (21.4%)	
12-19 years	45 (37.8%)	11 (78.6%)	
Hospital			0.03
Downstate	32 (26.9%)	8 (57.1%)	
Kings County	87 (73.1%)	6 (42.9%)	
Date presenting			0.003
MarDec. 2020	29 (24.4%)	0	
JanJune 2021	10 (8.4%)	0	
June-Nov. 2021	23 (19.3%)	0	
Nov. 2021-Mar. 2022	57 (47.9%)	14 (100%)	
Black race	90 (78.3%)	12 (85.7%)	0.7
Non-Hispanic ethnicity	105 (91.3%)	13 (92.9%)	1.0
Male sex	63 (52.9%)	9 (64.3%)	0.4
Preexisting conditions	52 (43.7%)	11 (78.6%)	0.01
Asthma	16 (13.4)	6 (42.9)	0.01
BMI, median, IQR	19.2 (16.8-24.5)	25.6 (19.0, 27.0)	0.02
BMI z-score, median (IQR)	0.47 (-0.40, 1.67)	1.21 (0.24, 1.81)	0.2
BMI z-score, mean (SD)	0.41 (1.75)	1.02 (1.25)	0.1

BMI class			0.2
0	68 (62.4%)	6 (42.9%)	
1	20 (18.3%)	3 (21.4%)	
2	21 (19.3%)	5 (35.7%)	
Missing	10 (8.4%)	0	
Presenting with GI symptoms	63 (52.9)	10 (71.4)	0.2
Presenting with nausea	31 (26.1)	3 (21.4)	1.0
Presenting with diarrhea	14 (11.8)	2 (14.3)	0.7
Presenting with decreased intake	18 (15.1)	1 (7.1)	0.7
Presenting with abdominal pain	22 (18.5)	5 (35.7)	0.2
Presenting with other GI symptoms	22 (18.5)	4 (28.6)	0.5
Level of care			0.3
ED and discharged	56 (47.1)	10 (71.4)	
Floor	45 (37.8)	3 (21.4)	
PICU	18 (15.1)	1 (7.1)	

P-value for continuous variables was from Wilcoxon test due to skewed distributions. P-value from categorical variable was from chi-square test.

Table 2: Demographics by	v transaminase elevation status
Tuble 2. Demographics b	y clansummase elevation status

	No elevated transaminases (n=80)	Elevated transaminases (n=53)	P-value
Vaccinated	11 (13.8%)	3 (5.7%)	0.1
Antibody positive (vs. no testing or negative)	23 (31.9)	6 (12.2)	0.01
AST, median, IQR	24 (18, 33) Range 12-46	56 (42, 72) Range (12-1137)	<0.001
AST elevations			
None [Normal AST ≤ 46]	80 (100)	19 (35.8)	
Mild [Abnormal, less than 2x ULN]	0	29 (54.7)	
Moderate [Between 2-5x ULN]	0	4 (7.5)	
Severe [More than 5x ULN]	0	1 (1.9)	
AST/ALT ratio, median, IQR	1.9 (1.5, 2.3) Range 0.6-8.40	2.1 (1.1, 3.2) Range 0.32-6.31	0.8
ALT, median, IQR	13.5 (11.0, 17.0)	27.0 (18.0, 41.0)	<0.001
Glucose, median, IQR	96.0 (89.0, 109.0)	98.0 (88.0, 107.0)	0.9
Albumin, median, IQR	4.55 (4.2, 4.8)	4.50 (3.9, 4.8)	0.6
Alkaline Phosphatase, median, IQR	181 (84.8, 241)	225 (133, 269)	0.05
Platelets, median, IQR	279 (217, 374)	270 (197.5, 352.5)	0.4
Total bilirubin	0.4 (0.2, 0.5)	0.4 (0.2, 0.7)	0.2
Age (months), median	144 (69, 201)	60 (13, 144)	<0.001
(interquartile range) (range)	Range 1-216	Range 1-223	
Age group			0.002
0-4 years	13 (16.2%)	21 (39.6%)	
5-11 years	25 (31.2%)	18 (34.0%)	
12-19 years	42 (52.5%)	14 (26.4%)	
Hospital			0.98
Downstate	24 (30.0%)	16 (30.2%)	
Kings County	56 (70.0%)	37 (69.8%)	
Date presenting			0.55
MarDec. 2020	20 (25.0%)	9 (17.0%)	
JanJune 2021	7 (8.8%)	3 (5.7%)	
June-Nov. 2021	14 (17.5%)	9 (17.0%)	
Nov. 2021-Mar. 2022	39 (48.8%)	32 (60.4%)	
Black race	61 (79.2%)	41 (78.8%)	0.96
Hispanic ethnicity	6 (7.8%)	5 (9.6%)	0.76
Male sex	37 (46.2%)	35 (66%)	0.02
Preexisting conditions	38 (47.5%)	25 (47.2%)	0.97
Asthma	19 (23.8)	3 (5.7)	0.006
BMI, median, IQR	20.0 (17.7, 26.0)	18.7 (16.5, 24.7)	0.2
BMI z-score, median (IQR)	0.56 (-0.41, 1.79)	0.79 (-0.22, 1.41)	1

BMI class			0.3
0	44 (55.0%)	30 (56.6%)	
1	12 (15.0%)	11 (20.8%)	
2	19 (23.8%)	7 (13.2%)	
Missing	5 (6.3%)	5 (9.4%)	
Presenting with GI symptoms	48 (60.0)	25 (47.2)	0.2
Presenting with nausea	19 (23.8)	15 (28.3)	0.6
Presenting with diarrhea	10 (12.5)	6 (11.3)	0.8
Presenting with diminished food intake	15 (18.8)	4 (7.5)	0.07
Presenting with other GI symptoms	20 (25.0)	6 (11.3)	0.05
Level of care			0.001
ED and discharged	49 (61.3%)	17 (32.1%)	
Floor	25 (31.2%)	23 (43.4%)	
PICU	6 (7.5%)	13 (24.5%)	

P-value for continuous variables was from Wilcoxon test due to skewed distributions. P-value from categorical variable was from chi-square test.